University of Virginia

A recent poll found 90% of Americans believe we're in a mental health crisis. Behavioral health practices must optimize operations, focusing on efficient intake processes, telehealth implementation, provider recruitment/retention, and high standards of care/compliance to ensure success and high-quality patient care.

Patients with peripheral neuropathy showed improvement in neuropathic pain with cannabis-based medicines, according to a systematic review in The Journal of Hand Surgery. 79% of studies reported positive outcomes, with mild side effects.

Dr. Gary Gibson hypothesizes that thiamine deficiency alters glucose metabolism in brain cells, leading to Alzheimer's. His research led to a nationwide clinical trial evaluating benfotiamine, an oral drug boosting thiamine levels, as a potential treatment.

Researchers at Baylor College of Medicine and Texas Children’s Hospital found that loss of MeCP2 in adulthood causes immediate gene dysregulation, leading to Rett syndrome. They identified a molecular cascade driving disease independently of developmental contributions, with neuronal circuit-level deficits occurring after gene expression dysregulation.

Newsweek’s Best-in-State Hospitals 2025 list ranks UVA Health University Medical Center as Virginia’s No. 1 hospital. The ranking is based on healthcare professionals’ surveys, patient survey data, hospital quality metrics, accreditations, and data from the American Hospital Association. UVA Health has seen significant growth, with a 54% rise in unique patients, 65% increase in surgical procedures, and 55% rise in outpatient encounters since 2019. The health system has also recruited 126 new physicians since July 2024, reinforcing its commitment to high-quality care and retention.

HK inno.N Corp. launched its GERD drug, K-CAB, in six Latin American countries, marking a global expansion milestone. K-CAB, a P-CAB treatment, has shown rapid efficacy and safety, achieving top sales in South Korea. The drug has entered 18 Latin American countries, with significant market penetration in Mexico. Academic conferences have promoted K-CAB, with Dr. David Pura endorsing its use in Helicobacter eradication therapies. HK inno.N aims to promote domestically developed drugs globally.

E. Madan led experiments, data analysis, and manuscript writing. A.M.P., V.V., A.K., and P.B. contributed to experiments, data analysis, and manuscript preparation. J.W. handled biostatistical analysis and data interpretation. T.B. and D.A. focused on microscopy, data interpretation, and figure preparation. P.C.M., G.B., M.D.B., I.D., H.K., and D.O. assisted with biostatistical analysis and data interpretation. A. Gogna and A.B. helped with figure preparation and live-cell videos. M.L.P., M.Y., D.Z., S.P., S.K., K.B., P.M., I.C., E.A.F., A.K.P., S.M., C.J.P., A.L., M.N., S.C., K.G., K.C.G., and K.S.S. contributed to pathology data collection and analysis. T.F.A., E.G., A. Gustafsson, G.L., L.N., E.Y., and R.S.-F. worked on 3D scaffold and organoid experiments. K.D.P.D. assisted with PDX experiments. N.M., M.J.P., K.J.-J., and S.H. focused on exosome biology experiments. Z.S. and W.L.R. worked on multiplexing experiments. M.B. and P.J. handled FISH experiments. H.O.R., F.A.T., and R.B. contributed to MR imaging data analysis. K.G.A., J.A., G.X., G.S., and S. Singh designed and produced mAbs. S.D., C.L.d.S., A.M.F., D.T., S.R.G., K.P., G.G., G.L.W.G.R., and H.W. edited the manuscript. A.M.H., A.R., and C.L. worked on mass spec analysis. A.S. and P.B.F. provided laboratory resources and collaboration. G.M.C., Y.L., A.L.O., L.L., and A.A.T. handled CRISPR-off experiments. A.S.P., U.M., R.D., A.K.G., K.S., and D. Chelmow contributed to ovarian cancer expertise. R.P., J.K., S.R., H.R., S. Sayeed, K.P.K., D. Connolly, K.P.N., M.O.I., M.P.K., C.M., M.A., A.L.-B., D.J., K.D.M., A. Tzankov, S.B., E.A.R., and R.C.M. assisted with pathology data collection. A. Tsung and D.S. fostered clinical collaborations. J.T. provided mouse tumor models and funding. A.P.S., R.W., K.J.W., and E. Moreno helped with manuscript writing and funding. R.G. designed the study, organized collaborations, and provided overall supervision and funding.

Laahn Foster, MD, discusses the phase 3 AURIGA study evaluating daratumumab plus lenalidomide vs lenalidomide alone as maintenance therapy in newly diagnosed multiple myeloma after transplant, presented at the 2024 ASH Annual Meeting.

BostonGene presents 12 abstracts at the 66th ASH Annual Meeting, highlighting AI-driven innovations in molecular and immunoprofiling for advancing cancer therapies.

Tonix Pharmaceuticals appoints Bradley Raudabaugh as VP of Marketing and Errol Gould as VP of Medical Affairs to support the launch of TNX-102 SL for fibromyalgia. The NDA for TNX-102 SL was submitted to the FDA in October 2024, with an expected decision in 2025, potentially marking the first new drug for fibromyalgia in over 15 years.